全球藥局市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計到 2034 年，配藥藥房市場規模將達到 319.8 億美元，而 2025 年為 197.5 億美元，預計 2026 年至 2034 年的複合年成長率將達到 5.5%。

全球藥局市場正穩定成長，其主要驅動力是患者對個人化醫療日益成長的需求。當市售藥物無法滿足特定劑量或成分要求時，藥局會配製定製配方。這種方法對於過敏患者、兒童患者以及需要特殊藥物組合的患者尤其重要。慢性病盛行率的上升以及對最佳化患者治療方案需求的日益成長，也推動了這個市場的擴張。

推動市場成長的另一個因素是人們對個人化醫療和專科藥品的日益關注。藥房正在荷爾蒙補充療法、疼痛管理、皮膚病學和獸醫學等領域提供客製化解決方案。此外，藥品分發設備的科技進步和法規結構的完善正在提升產品的安全性和品質。醫療服務提供者正擴大與藥房合作，以提供以患者為中心的治療方案。

未來幾年，隨著個人化醫療日益重要，藥局市場預計將持續擴張。對藥物研發投入的增加，以及醫療專業人員對個人化用藥認知的不斷提高，都將推動市場成長。此外，配藥技術的進步和法律規範的加強有望提升全球處方藥的可靠性和可及性。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球藥局市場：依治療領域分類

• 市場分析、洞察與預測
• 荷爾蒙補充療法
• 疼痛管理
• 特種藥品
• 皮膚科
• 營養補充品
• 其他

第5章：全球藥局市場：依年齡層別分類

• 市場分析、洞察與預測
• 兒童
• 成人
• 老年人

第6章：全球藥局市場：依配藥類型分類

• 市場分析、洞察與預測
• 藥物成分變更（PIA）
• 目前無法提供藥品生產（CUPM）
• 藥物劑量調整（PDA）
• 其他

第7章：全球藥局市場：無菌性

• 市場分析、洞察與預測
• 無菌
• 非無菌

第8章：全球藥局市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Walgreen Co
  • JL Diekman And AQ Touchard（Fresh Therapeutics Compounding Pharmacy）
  • Fagron
  • Albertsons Companies
  • The London Specialist Pharmacy Ltd（Specialist Pharmacy）
  • Galenic Laboratories Limited（Roseway Labs）
  • Aurora Compounding
  • MEDS Pharmacy
  • Apollo Clinical Pharmacy
  • Formul8
  • Fusion Apothecary

The Compounding Pharmacies Market size is expected to reach USD 31.98 Billion in 2034 from USD 19.75 Billion (2025) growing at a CAGR of 5.5% during 2026-2034.

The global compounding pharmacies market is growing steadily due to increasing demand for personalized medications tailored to individual patient needs. Compounding pharmacies prepare customized formulations when commercially available drugs do not meet specific dosage or ingredient requirements. This practice is particularly important for patients with allergies, pediatric patients, and individuals requiring specialized drug combinations. The rising prevalence of chronic diseases and the growing need for patient-specific treatments are supporting the expansion of this market.

Another factor driving market growth is the increasing focus on personalized medicine and specialty pharmaceuticals. Compounding pharmacies provide customized solutions in areas such as hormone replacement therapy, pain management, dermatology, and veterinary medicine. In addition, technological advancements in pharmaceutical compounding equipment and improved regulatory frameworks are enhancing product safety and quality. Healthcare providers are increasingly collaborating with compounding pharmacies to deliver tailored treatment solutions.

In the coming years, the compounding pharmacies market is expected to expand as personalized healthcare becomes more prominent. Rising investments in pharmaceutical research and development and growing awareness among healthcare professionals about customized medications will support market growth. Furthermore, advancements in compounding technologies and regulatory oversight are likely to enhance the credibility and adoption of compounded pharmaceutical products worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Area

• Hormone Replacement Therapy
• Pain Management
• Specialty Drugs
• Dermatology
• Nutritional Supplements
• Others

By Age Cohort

• Pediatric
• Adult
• Geriatric

By Compounding Type

• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)
• Others

By Sterility

• Sterile
• Non-sterile

COMPANIES PROFILED

• Walgreen Co, JL Diekman and AQ Touchard Fresh Therapeutics Compounding Pharmacy, Fagron, Albertsons Companies, The London Specialist Pharmacy Ltd Specialist Pharmacy, Galenic Laboratories Limited Roseway Labs, Aurora Compounding, MEDS Pharmacy, Apollo Clinical Pharmacy, Formul8, Fusion Apothecary
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPOUNDING PHARMACIES MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Area
• 4.2. Hormone Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pain Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Specialty Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Nutritional Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPOUNDING PHARMACIES MARKET: BY AGE COHORT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Age Cohort
• 5.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPOUNDING PHARMACIES MARKET: BY COMPOUNDING TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Compounding Type
• 6.2. Pharmaceutical Ingredient Alteration (PIA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pharmaceutical Dosage Alteration (PDA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPOUNDING PHARMACIES MARKET: BY STERILITY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Sterility
• 7.2. Sterile Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Non-sterile Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL COMPOUNDING PHARMACIES MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapeutic Area
  • 8.2.2 By Age Cohort
  • 8.2.3 By Compounding Type
  • 8.2.4 By Sterility
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapeutic Area
  • 8.3.2 By Age Cohort
  • 8.3.3 By Compounding Type
  • 8.3.4 By Sterility
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapeutic Area
  • 8.4.2 By Age Cohort
  • 8.4.3 By Compounding Type
  • 8.4.4 By Sterility
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapeutic Area
  • 8.5.2 By Age Cohort
  • 8.5.3 By Compounding Type
  • 8.5.4 By Sterility
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapeutic Area
  • 8.6.2 By Age Cohort
  • 8.6.3 By Compounding Type
  • 8.6.4 By Sterility
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL COMPOUNDING PHARMACIES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Walgreen Co
  • 10.2.2 JL Diekman And AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
  • 10.2.3 Fagron
  • 10.2.4 Albertsons Companies
  • 10.2.5 The London Specialist Pharmacy Ltd (Specialist Pharmacy)
  • 10.2.6 Galenic Laboratories Limited (Roseway Labs)
  • 10.2.7 Aurora Compounding
  • 10.2.8 MEDS Pharmacy
  • 10.2.9 Apollo Clinical Pharmacy
  • 10.2.10 Formul8
  • 10.2.11 Fusion Apothecary